-
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Albany, Laurelton, Long Island City
-
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: The Bronx
-
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn
-
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn
-
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 55 Years and older ·
Sex: All (male and female)
· New York: Brooklyn, Jackson Heights, Lake Success, Mount Kisco
-
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
NCT07061574 ·
Phase: Phase 1, Phase 2 ·
Ages: 9 Years to 20 Years ·
Sex: All (male and female)
· New York: Buffalo
-
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Albany
-
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: West Seneca
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613 ·
Phase: Phase 3 ·
Ages: 10 Years to 18 Years ·
Sex: All (male and female)
· New York: Buffalo, New York
-
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 ·
Phase: Phase 3 ·
Ages: 18 Years to 79 Years ·
Sex: All (male and female)
· New York: Albany, Brooklyn, The Bronx
-
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
NCT07340320 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: Brooklyn
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· New York: Buffalo, Hyde Park, Syracuse
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Long Island City
-
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Rochester
-
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: Long Island City, Staten Island, West Seneca
-
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: East Northport, East Syracuse, New Windsor
-
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Cortland
-
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Manlius
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: Amherst, Rochester
-
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
NCT07595549 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, Rochester
-
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn
-
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07533175 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: West Seneca
-
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335 ·
Phase: Phase 3 ·
Ages: 45 Years and older ·
Sex: All (male and female)
· New York: Manlius, New Windsor, New York, The Bronx
-
APP-MNT: App-Enhanced Medical Nutrition Therapy on Glycemic Outcomes and Quality of Life
NCT07773779 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York
-
Alpelisib Challenge Test (ACT)
NCT07778524 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· New York: New York
-
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
NCT06959277 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 55 Years and older ·
Sex: All (male and female)
· New York: Amherst
-
CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes
NCT07140848 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
NCT06525259 ·
Phase: Not specified ·
Ages: 8 Years to 15 Years ·
Sex: All (male and female)
· New York: Brooklyn, Garden City, New York, The Bronx
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Albany, Binghamton, Buffalo, New York
-
ED Diabetes Screening and Outpatient Care - Aim 3
NCT05899023 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 20 Years to 70 Years ·
Sex: All (male and female)
· New York: New York
-
Effects of HIIT vs. TRE on Type 2 Diabetes Risk
NCT07215533 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 14 Years to 30 Years ·
Sex: All (male and female)
· New York: Syracuse
-
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
NCT07521475 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York, Syracuse
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
NCT07228117 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 7 Years to 85 Years ·
Sex: All (male and female)
· New York: Long Island City
-
Graded Insulin Suppression Test P&F
NCT06592261 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
NCT06329544 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 25 Years to 45 Years ·
Sex: All (male and female)
· New York: New York
-
Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
NCT07641361 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· New York: Buffalo
-
Implementing an Effective Diabetes Intervention Among Low-Income Immigrants
NCT06319703 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· New York: New York
-
In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes
NCT06557317 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 12 Years to 18 Years ·
Sex: Female
· New York: Brooklyn
-
LINK-IT: Leveraging vIdeos and commuNity Health worKers to Improve Diabetes OuTcomes
NCT06319716 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Milk for Diabetes Prevention
NCT06513026 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· New York: The Bronx
-
NYSCF Scientific Discovery Biobank
NCT06203106 ·
Phase: Not specified ·
Ages: 30 Days and older ·
Sex: All (male and female)
· New York: New York
-
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
NCT07106879 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn
-
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
NCT05884775 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892 ·
Phase: Phase 4 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female)
· New York: New York
-
Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
NCT07216391 ·
Phase: Phase 2 ·
Ages: 4 Years to 34 Years ·
Sex: All (male and female)
· New York: New York
-
RESET System Pivotal Trial (Rev F)
NCT04101669 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
Real World Evidence Clinical Utility Study of KidneyIntelX
NCT04802395 ·
Phase: Not specified ·
Ages: 23 Years and older ·
Sex: All (male and female)
· New York: New York
-
Registry for Stage 2 Type 1 Diabetes
NCT06481904 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· New York: Buffalo, Manhasset, Staten Island, Syracuse
-
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: Albany
-
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
NCT07271186 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: Binghamton, The Bronx
-
Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility
NCT06412536 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Albany